NEW YORK (GenomeWeb News) – Enzo Biochem has filed a shelf registration to separately offer up to $50 million of its securities and another $18 million of its common stock.

Enzo filed two prospectuses in a Form S-3 with the US Securities and Exchange Commission on Thursday. In one, the New York-based life science reagents and diagnostic testing firm said it may offer from time to time its common stock, preferred stock, depositary shares, debt securities, warrants, and units totaling no more than $50 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.